Market view
Stock chart
Coverage
Analyses on Allmed Solution (3)
- March 30, 2026March 30, 2026
- Follow-up
Olmed Solutions: What Really Remains in UniGrd and Whether It Can Become a Deal
UniGrd remains inside Olmed as a narrow but real carotid transaction package, with retained approvals and a global use license, but it affects the funding story only if buyer-search language turns into an actual transaction.
- Follow-up
Olmed Solutions: How Much of Theroleaf's Value Really Reaches Shareholders
Theroleaf may create material value for Olmed, but not all of that value belongs or is accessible to common shareholders: Olmed is at 68.48% on a fully diluted basis, a legacy seller layer still sits above that, and Innovation Authority royalties and restrictions add another fil…
Olmed Solutions 2025: Clinical Proof Has Started, but the Financing Test Is Still Ahead
Theroleaf's 2025 clinical progress turns Olmed into a proof story rather than only a promise story, but without broader financing and repeatable full procedures the thesis remains incomplete.
Same sector
